

Invited Review for the 2009 Hiroshi Kuriyama Award

Regulation of vascular tone and remodeling of the ductus arteriosus

Utako YOKOYAMA¹, Susumu MINAMISAWA² and Yoshihiro ISHIKAWA¹

¹*Cardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Japan*

²*Department of Life Science and Medical Bioscience, Waseda University Graduate School of Advanced Science and Engineering, Japan*

Received January 6, 2010; Accepted January 10, 2010

Abstract

The ductus arteriosus (DA), a fetal arterial connection between the main pulmonary artery and the descending aorta, normally closes immediately after birth. The DA is a normal and essential fetal structure. However, it becomes abnormal if it remains patent after birth. Closure of the DA occurs in two phases: functional closure of the lumen within the first hours after birth by smooth muscle constriction, and anatomic occlusion of the lumen over the next several days due to extensive neointimal thickening in human DA. There are several events that promote the DA constriction immediately after birth: (a) an increase in arterial oxygen tension, (b) a dramatic decline in circulating prostaglandinE₂ (PGE₂), (c) a decrease in blood pressure within the DA lumen, and (d) a decrease in the number of PGE₂ receptors in the DA wall. Anatomical closure of the DA is associated with the formation of intimal thickening, which are characterized by (a) an area of subendothelial deposition of extracellular matrix, (b) the disassembly of the internal elastic lamina and loss of elastic fiber in the medial layer, and (c) migration into the subendothelial space of undifferentiated medial smooth muscle cells. In addition to the well-known vasodilatory role of PGE₂, our findings uncovered the role of PGE₂ in anatomical closure of the DA. Chronic PGE₂-EP4-cyclic AMP (cAMP)-protein kinase A (PKA) signaling during gestation induces vascular remodeling of the DA to promote hyaluronan-mediated intimal thickening and structural closure of the vascular lumen. A novel target of cAMP, Epac, has an acute promoting effect on smooth muscle cell migration without hyaluronan production and thus intimal thickening in the DA. Both EP4-cAMP downstream targets, Epac and PKA, regulate vascular remodeling in the DA.

Key words: cyclic AMP, exchange protein activated by cyclic AMP (EPAC), protein kinase A, intimal thickening, the ductus arteriosus, vascular remodeling, hyaluronan

Correspondence to: Utako Yokoyama, MD, PhD, Cardiovascular Research Institute, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku Yokohama City 236-0004, Japan
Phone: +81-45-787-2575 Fax: +81-45-788-1470 e-mail: utako@yokohama-cu.ac.jp
UY was the winner of the Hiroshi Kuriyama Award.

Introduction

The ductus arteriosus (DA), a fetal arterial connection between the pulmonary artery and the descending aorta, is indispensable for fetal life. It shunts deoxygenated blood from the main pulmonary artery to the descending aorta. Over half of the blood flow in the descending aorta is diverted to the umbilico-placental circulation (Heymann and Rudolph, 1975), where gaseous exchange takes place. Although patency of the DA is required for fetal survival, the persistence of a patent DA after birth is a major cause of morbidity and mortality, especially in premature infants, leading to severe complications, including pulmonary hypertension, right ventricular dysfunction, postnatal infections and respiratory failure (Hermes-DeSantis and Clyman, 2006). The incidence of DA patency has been estimated to be one in 500 in term newborns and accounts for the majority of all cases of congenital heart diseases in preterm newborns (Mitchell *et al.*, 1971). In preterm babies with birth weights <1,500 g, the incidence of a patent DA exceeds 30% (Van Overmeire *et al.*, 2004). In addition, the presence of a patent DA is more serious in premature infants than in full-term infants since premature infants with a patent DA are more likely to develop problems such as intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary dysplasia and congestive heart failure. Therefore, it is important to understand the precise mechanisms of regulation of the DA.

Closure of the human DA is believed to occur in two phases: (1) functional closure of the lumen within the first hours after birth by smooth muscle constriction, and (2) anatomic occlusion of the lumen over the next several days due to extensive neointimal thickening and loss of smooth muscle cells from the inner muscle media (Smith, 1998; Clyman, 2006; Yokoyama *et al.*, 2006b). Although its process is similar in mammalian DA, the time course of two phases is variable among species. There are several events that promote the DA constriction immediately after birth: (a) an increase in arterial oxygen tension, (b) a dramatic decline in circulating prostaglandinE₂ (PGE₂) because of metabolism in the now functioning lungs and elimination of the placental source, (c) a decrease in blood pressure within the DA lumen, and (d) a decrease in the number of PGE₂ receptors in the DA wall (Smith, 1998; Clyman, 2006).

The DA later undergoes permanent closure through structural remodeling and fibrosis. The resulting fibrous band with no lumen persists as the ligamentum arteriosum (Fay and Cooke, 1972). Anatomical closure of the DA is associated with the formation of intimal thickening, which are characterized by (a) an area of subendothelial deposition of extracellular matrix, (b) the disassembly of the internal elastic lamina and loss of elastic fiber in the medial layer, and (c) migration into the subendothelial space of undifferentiated medial smooth muscle cells (Smith, 1998). Some of these changes begin about halfway through gestation and some occur after functional closure of the DA in the neonate (Slomp *et al.*, 1997; Yokoyama *et al.*, 2006b). This cascade of events is thought to orchestrate the subsequent luminal DA reorganization, leading finally to complete obliteration of the DA. In this report, we review the current state of knowledge of the mechanisms of regulating vascular tone and remodeling of the DA.

1. Functional closure of the DA

1-1. Oxygen-induced contraction

During the fetal life, the DA is exposed to an oxygen tension that has been estimated as between 18 to 28 mmHg (Heymann and Rudolph, 1975). After birth, the DA is exposed to arterial blood and arterial oxygen tension rises rapidly after delivery. Rising oxygen tension significantly contracts the DA (Smith, 1998). With the exception of the pulmonary artery, most vascular smooth muscles relax in a low oxygen environment and contract in response to increasing oxygen tension. However, the response of the DA to oxygen is much greater in magnitude, although qualitatively similar to other vessels (Heymann and Rudolph, 1975; Smith and McGrath, 1988).

Several mechanisms have been proposed to explain the contractile effect of raising oxygen tension in the DA. The increase in oxygen tension inhibits ductal smooth muscle voltage-dependent potassium channels (Michelakis *et al.*, 2000; Reeve *et al.*, 2001), such as Kv1.5 and Kv2.1, which results in membrane depolarization, an influx of calcium and DA constriction (Nakanishi *et al.*, 1993; Leonhardt *et al.*, 2003). The inhibition of potassium channels is associated with production of diffusible redox mediator (H_2O_2) by a mitochondrial O_2 -sensor, electron transport chain complexes I or III in the DA (Archer *et al.*, 2004). It has been reported that ATP-sensitive potassium channel was inhibited by the raising oxygen tension, resulting in membrane depolarization (Nakanishi *et al.*, 1993). In addition to involvement of potassium channels, recent study reported that depolarization-independent DA contraction is caused by release of calcium from the IP_3 -sensitive store in the sarcoplasmic reticulum. Subsequent calcium entry through store-operated channels increases an influx of calcium and DA constriction (Hong *et al.*, 2006). Schematic illustration of the functional closure of the DA is shown in Figure 1.

Calcium entry through L-type voltage-dependent calcium channels is involved in oxygen-induced DA contraction (Tristani-Firouzi *et al.*, 1996). Our previous study demonstrated that among L-type calcium channels, Cav1.2 was predominant isoform and expression level of Cav1.2 was higher in the rat DA than in the aorta (Yokoyama *et al.*, 2006a). Calcium influx through T-type voltage-dependent calcium channels, especially Cav3.1, also promoted oxygenation-induced DA constriction (Nakanishi *et al.*, 1993; Akaike *et al.*, 2009).

Coceani *et al.* reported that cytochrome P_{450} was the oxygen sensor and its activation promoted DA contraction through production of endothelin-1 (ET-1) from endothelium and smooth muscle of the DA (Coceani and Kelsey, 1991; Coceani *et al.*, 1992). They demonstrated stimulation of endothelin A receptor (ET_A) is associated with oxygen-induced DA contraction using mice with genetic disruption of ET_A (Coceani *et al.*, 1999). However, the DA was normally closed after birth in ET_A knockout mice. Consequently, ET-1- ET_A signaling plays a role in oxygen-induced contraction, but not in anatomical closure in the DA.

Vitamin A and/or retinoic acid signaling is a candidate for the activator of oxygen sensitivity, because the retinoic acid response element is strongly expressed in the mouse DA (Colbert *et al.*, 1996), and maternally administered vitamin A accelerated development of the oxygen-sensing mechanism of the rat DA (Wu *et al.*, 2001). Our study demonstrated that




Fig. 1. A schematic model of functional closure of the DA. K^+ : potassium ion, Ca^{2+} : calcium ion, O_2 : oxygen, O_2^- : superoxide anion, H_2O_2 : hydrogen peroxide, ATP: adenosine triphosphate, K_{ATP} : ATP-dependent potassium channel, VDCC: voltage-dependent potassium channel, VDCC: voltage-dependent calcium channel, SOC: store-operated calcium channel, Mt: mitochondria, SR/ER: sarco/endoplasmic reticulum, IP3: inositol triphosphate, IP3R: IP3 receptor, PLC: phospholipase C, MLCK: myosin light chain kinase, CYP: cytochrome P_{450} .

maternally administered vitamin A increased the expression levels of Cav1.2 and Cav3.1 in the rat DA (Yokoyama *et al.*, 2006a).

1-2. Rapid withdrawal of the vasodilator effect of PGE_2

PGE_2 is produced in the placenta (Smith, 1998) and the DA (Clyman *et al.*, 1978; Cocceani *et al.*, 1978) and contributes to the DA patency in utero. Stimulation of PGE_2 receptors activates adenylyl cyclases (Bouayad *et al.*, 2001). The increased intracellular concentrations of cyclic AMP (cAMP) inhibit myosin light chain kinase, resulting in the DA relaxation (Smith, 1998). The dilator effect of PGE_2 on the rabbit DA was mediated by the PGE_2 receptor, EP4 (Smith and McGrath, 1994). After birth, the high fetal circulating concentrations of PGE_2 dramatically decline because the placenta is removed and the lung promotes catabolism of PGE_2 (Smith, 1998). Further, the expressions of PGE_2 receptors were decreased in the DA wall (Smith, 1998; Clyman, 2006).

Both isoforms of the enzyme responsible for synthesizing PGE_2 , cyclooxygenase (COX)-1 and COX-2, are expressed in the fetal DA (Takahashi *et al.*, 2000). Since COX-2 expression in the fetal DA significantly increased with advancing gestational age (Trivedi *et al.*, 2006), COX-2 inhibitor-induced DA contraction is weaker in preterm rats on the 19th day of gestation than in near-term on the 21st day (Toyoshima *et al.*, 2006). A COX inhibitor is widely used for the patent DA, however, this may not be a better therapy for premature infants with patent DA.

1-3. Other factors mediating contraction of the DA

It has been reported that nitric oxide (NO) plays a role in vasodilation of the DA. NO is synthesized by endothelial nitric oxide synthase (eNOS) in the luminal endothelium and the vasovasorum endothelium and induces relaxation of the DA through cyclic GMP (cGMP) signaling (Clyman, 2006). The relative importance of the cAMP and cGMP has been studied. Adenylyl cyclase stimulator, forskolin completely reversed the combined contractile effects of elevated oxygen tension, norepinephrin and COX inhibitor, whereas inhibition of cGMP signaling by sodium nitroprusside caused 4% of the effect of forskolin (Smith and McGrath, 1993). This implies that cAMP signaling is more important than cGMP signaling in near-term DA. On the other hand, in premature DA, the combined use of an NO synthase-inhibitor and COX inhibitor produces a much greater degree of the DA contraction than COX inhibitor alone (Seidner *et al.*, 2001).

2. Anatomical closure of the DA

2-1. Histological change during perinatal period

After birth, there is extensive remodeling of the DA wall, which leads to permanent closure of the DA. Intimal thickening, a characteristic developmental remodeling process in the DA, is required for postnatal DA closure (Rabinovitch, 1996; Mason *et al.*, 1999; Yokoyama *et al.*, 2006b). Intimal thickening starts with lifting of the endothelial cells (Gittenberger-de Groot *et al.*, 1985) and accumulations of hyaluronan in the subendothelial region, creating a space that is suitable for migration of smooth muscle cells through the fragmented elastic lamina into the subendothelial region (De Reeder *et al.*, 1988). Figure 2 shows histological change of the rat DA. Intimal thickening is developed in mature rat DA on the 21st day of gestation, while it is lacked in immature DA on the 19th day of gestation. Since intimal thickening is poorly developed in human patent DA patients and animal models of patent DA (Gittenberger-de Groot *et al.*, 1980; Gittenberger-de Groot *et al.*, 1985; Tada *et al.*, 1985), this process plays an important role in permanent closure of the DA after birth.

2-2. Molecular mechanisms of regulating intimal thickening

PGE₂ plays a primary role in maintaining the patency of DA, however, previous studies have demonstrated that genetic disruption of the PGE receptor EP4 paradoxically results in fatal patent DA in mice (Nguyen *et al.*, 1997; Segi *et al.*, 1998). In addition, double mutant mice in which COX-1 and COX-2 are disrupted also exhibit patent DA (Loftin *et al.*, 2001). We found that intimal thickening was completely absent in the DA from EP4-disrupted neonatal mice (Yokoyama *et al.*, 2006b). Moreover, a marked reduction in hyaluronan production was found in EP4-disrupted DA, whereas a thick layer of hyaluronan deposit was present in wild-type DA. PGE₂-EP4-cAMP-protein kinase A (PKA) signaling up-regulates hyaluronan synthase type 2 mRNA, which increases hyaluronan production in the DA. Accumulation of hyaluronan then promotes smooth muscle cell migration into the subendothelial layer to form intimal thickening (Yokoyama *et al.*, 2006b). Signals through PGE₂-EP4 have two essential roles in DA development, namely, vascular dilation and intimal thickening.




Fig. 2. Developmental changes in intimal thickening in rat DA. (A) Elastica van Gieson staining shows that intimal thickening was poor on the 19th day of gestation (immature), whereas it became apparent on the 21st day of gestation (mature) and 4 hours after birth (at birth). (B) DA intimal thickening are also shown at higher magnification.

A new target of cAMP, *i.e.*, an exchange protein activated by cAMP, has recently been discovered; it is called Epac (de Rooij *et al.*, 1998). Epac has been known to exhibit a distinct cAMP signaling pathway that is independent of PKA (Bos, 2003). Our previous study demonstrated that Epac, which is up-regulated during the perinatal period, had an acute promoting effect on smooth muscle cell migration without hyaluronan production and thus intimal thickening in the DA (Yokoyama *et al.*, 2008). Therefore, both EP4-cAMP downstream targets, Epac and PKA, induced intimal thickening in the DA (Fig. 3).

T-type voltage-dependent calcium channels, especially Cav3.1, promoted oxygenation-induced DA constriction (Akaike *et al.*, 2009). Our study revealed that Cav3.1 was significantly up-regulated in oxygenated rat DA tissue and in the region of intimal thickening of DA and that Cav1.3 promoted smooth muscle cell migration. These results indicate that Cav1.3 promotes oxygenation-induced DA closure through smooth muscle cell migration and vasoconstriction in rats (Akaike *et al.*, 2009). We also found that a novel spliced variant of the alpha1C-subunit was highly expressed in the neointima cushion of the DA (Yokoyama *et al.*, 2006a), although a role of the novel isoform is needed to be studied.




Fig. 3. A schematic model of the diverse cAMP signaling pathway. Both Epac and PKA synergistically promoted intimal cushion formation in the DA, but they work in two distinct ways: Epac-mediated (acute) and PKA-mediated (chronic) promotion. AC: adenylyl cyclase.

2-3. Extracellular matrix in the DA

Vascular cells are defined by the ways in which they regulate their extracellular matrix, and changes in the extracellular matrix, in turn, determine vascular cell phenotype, *i.e.*, the ability to differentiate, proliferate, and migrate (Rabinovitch, 1996). It has been reported that DA smooth muscle cells produce two-fold more fibronectin than aortic smooth muscle cells (Rabinovitch, 1996). Mason *et al.* have demonstrated that preventing fibronectin-dependent intimal thickening would be a feasible manipulation to cause patent DA as a mode of treatment of congenital heart diseases (Mason *et al.*, 1999). Our previous study also demonstrated that maternally administered vitamin A increased fibronectin production and intimal thickening in the rat DA (Yokoyama *et al.*, 2007). Transforming growth factor beta and NO induce extracellular matrix including hyaluronan and fibronectin in DA smooth muscle cell (Rabinovitch, 1996).

Versican, an hyaluronan binding proteoglycan, plays an important role in proliferation and migration of vascular smooth muscle cells (Evanko *et al.*, 1999). Tanacin, a hexameric glycoprotein, also has been known to regulate vascular smooth muscle cell proliferation (Cowan *et al.*, 2000). Therefore, fibronectin and hyaluronan may not be the sole constituents of extracellular matrix in DA intimal thickening.

Closing remarks

The ductal closure occurs in two phases. During first few hours after birth in term newborns, there is acute and functional closure as a result of smooth muscle contraction of the

DA, which is triggered by an increase in oxygen tension and a decline in levels of circulating PGE₂. Importantly, prior to this, anatomical luminal narrowing develops through intimal thickening that occludes the vascular lumen and results in permanent closure after birth. Both PGE₂-EP4-cAMP downstream targets, Epac and PKA, induce intimal thickening in the DA. Chronic activation of EP4 induces hyaluronan-mediated smooth muscle cell migration via PKA, resulting in intimal thickening. Epac has an acute promoting effect on smooth muscle cell migration without hyaluronan production and thus intimal thickening in the DA.

Acknowledgements

This work was supported by grants from the Grant-in-Aid for Scientific Research (KAKENHI) (U.Y.), the Ministry of Health Labor and Welfare (S.M., Y.I.), the Ministry of Education, Culture, Sports, Science and Technology of Japan (S.M., Y.I.), the Yokohama Foundation for Advanced Medical Science (U.Y., S.M.), the Kanae Foundation for the Promotion for Medical Science (U.Y.), the Miyata Cardiology Research Promotion Funds (U.Y., S.M.), the Takeda Science Foundation (U.Y., S.M.), the Sumitomo Foundation (U.Y.), the Japan Heart Foundation Research Grant (U.Y.), the Kowa Life Science Foundation (U.Y.), the Cosmetology Research Foundation (Y.I.), the Uehara Memorial Foundation (U.Y.), the Kitsuen Research Foundation (Y.I.), "High-Tech Research Center" Project for Private Universities: MEXT (S.M.), Waseda University Grant for Special Research Projects (S.M.), The Vehicle Racing Commemorative Foundation (S.M.), and the Japan Space Forum (Y.I.).

References

- Akaike, T., Jin, M.H., Yokoyama, U., Izumi-Nakaseko, H., Jiao, Q., Iwasaki, S., Iwamoto, M., Nishimaki, S., Sato, M., Yokota, S., Kamiya, Y., Adachi-Akahane, S., Ishikawa, Y. and Minamisawa, S. (2009). T-type Ca²⁺ channels promote oxygenation-induced closure of the rat ductus arteriosus not only by vasoconstriction but also by neointima formation. *J. Biol. Chem.* **284**: 24025–24034.
- Archer, S.L., Wu, X.C., Thebaud, B., Moudgil, R., Hashimoto, K. and Michelakis, E.D. (2004). O₂ sensing in the human ductus arteriosus: redox-sensitive K⁺ channels are regulated by mitochondria-derived hydrogen peroxide. *Biol. Chem.* **385**: 205–216.
- Bos, J.L. (2003). Epac: a new cAMP target and new avenues in cAMP research. *Nat. Rev. Mol. Cell Biol.* **4**: 733–738.
- Bouayad, A., Kajino, H., Waleh, N., Fouron, J.C., Andelfinger, G., Varma, D.R., Skoll, A., Vazquez, A., Gobeil, F., Jr., Clyman, R.I. and Chemtob, S. (2001). Characterization of PGE₂ receptors in fetal and newborn lamb ductus arteriosus. *Am. J. Physiol.* **280**: H2342–H2349.
- Clyman, R.I. (2006). Mechanisms regulating the ductus arteriosus. *Biol. Neonate* **89**: 330–335.
- Clyman, R.I., Mauray, F., Roman, C. and Rudolph, A.M. (1978). PGE₂ is a more potent vasodilator of the lamb ductus arteriosus than is either PGI₂ or 6 keto PGF₁α. *Prostaglandins* **16**: 259–264.
- Cocceani, F., Bodach, E., White, E., Bishai, I. and Olley, P.M. (1978). Prostaglandin I₂ is less relaxant than prostaglandin E₂ on the lamb ductus arteriosus. *Prostaglandins* **15**: 551–556.
- Cocceani, F. and Kelsey, L. (1991). Endothelin-1 release from lamb ductus arteriosus: relevance to postnatal closure of the vessel. *Can. J. Physiol. Pharmacol.* **69**: 218–221.
- Cocceani, F., Kelsey, L. and Seidlitz, E. (1992). Evidence for an effector role of endothelin in closure of the ductus arteriosus at birth. *Can. J. Physiol. Pharmacol.* **70**: 1061–1064.

- Coceani, F., Liu, Y., Seidlitz, E., Kelsey, L., Kuwaki, T., Ackerley, C. and Yanagisawa, M. (1999). Endothelin A receptor is necessary for O₂ constriction but not closure of ductus arteriosus. *Am. J. Physiol.* **277**: H1521–H1531.
- Colbert, M.C., Kirby, M.L. and Robbins, J. (1996). Endogenous retinoic acid signaling colocalizes with advanced expression of the adult smooth muscle myosin heavy chain isoform during development of the ductus arteriosus. *Circ. Res.* **78**: 790–798.
- Cowan, K.N., Jones, P.L. and Rabinovitch, M. (2000). Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. *J. Clin. Invest.* **105**: 21–34.
- De Reeder, E.G., Girard, N., Poelmann, R.E., Van Munsteren, J.C., Patterson, D.F. and Gittenberger-De Groot, A.C. (1988). Hyaluronic acid accumulation and endothelial cell detachment in intimal thickening of the vessel wall. The normal and genetically defective ductus arteriosus. *Am. J. Pathol.* **132**: 574–585.
- de Rooij, J., Zwartkruis, F.J., Verheijen, M.H., Cool, R.H., Nijman, S.M., Wittinghofer, A. and Bos, J.L. (1998). Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. *Nature* **396**: 474–477.
- Evanko, S.P., Angello, J.C. and Wight, T.N. (1999). Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. *Arterioscler. Thromb. Vasc. Biol.* **19**: 1004–1013.
- Fay, F.S. and Cooke, P.H. (1972). Guinea pig ductus arteriosus. II. Irreversible closure after birth. *Am. J. Physiol.* **222**: 841–849.
- Gittenberger-de Groot, A.C., Strengers, J.L., Mentink, M., Poelmann, R.E. and Patterson, D.F. (1985). Histologic studies on normal and persistent ductus arteriosus in the dog. *J. Am. Coll. Cardiol.* **6**: 394–404.
- Gittenberger-de Groot, A.C., van Ertbruggen, I., Moulart, A.J. and Harinck, E. (1980). The ductus arteriosus in the preterm infant: histologic and clinical observations. *J. Pediatr.* **96**: 88–93.
- Hermes-DeSantis, E.R. and Clyman, R.I. (2006). Patent ductus arteriosus: pathophysiology and management. *J. Perinatol.* **26 Suppl. 1**: S14–18; discussion S22–13.
- Heymann, M.A. and Rudolph, A.M. (1975). Control of the ductus arteriosus. *Physiol. Rev.* **55**: 62–78.
- Hong, Z., Hong, F., Olschewski, A., Cabrera, J.A., Varghese, A., Nelson, D.P. and Weir, E.K. (2006). Role of store-operated calcium channels and calcium sensitization in normoxic contraction of the ductus arteriosus. *Circulation* **114**: 1372–1379.
- Leonhardt, A., Glaser, A., Wegmann, M., Schranz, D., Seyberth, H. and Nusing, R. (2003). Expression of prostanoid receptors in human ductus arteriosus. *Br. J. Pharmacol.* **138**: 655–659.
- Loftin, C.D., Trivedi, D.B., Tiano, H.F., Clark, J.A., Lee, C.A., Epstein, J.A., Morham, S.G., Breyer, M.D., Nguyen, M., Hawkins, B.M., Goulet, J.L., Smithies, O., Koller, B.H. and Langenbach, R. (2001). Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. *Proc. Natl. Acad. Sci. USA* **98**: 1059–1064.
- Mason, C.A., Bigras, J.L., O'Blenes, S.B., Zhou, B., McIntyre, B., Nakamura, N., Kaneda, Y. and Rabinovitch, M. (1999). Gene transfer in utero biologically engineers a patent ductus arteriosus in lambs by arresting fibronectin-dependent neointimal formation. *Nat. Med.* **5**: 176–182.
- Michelakis, E., Rebeyka, I., Bateson, J., Olley, P., Puttagunta, L. and Archer, S. (2000). Voltage-gated potassium channels in human ductus arteriosus. *Lancet* **356**: 134–137.
- Mitchell, S.C., Korones, S.B. and Berendes, H.W. (1971). Congenital heart disease in 56,109 births. Incidence and natural history. *Circulation* **43**: 323–332.
- Nakanishi, T., Gu, H., Hagiwara, N. and Momma, K. (1993). Mechanisms of oxygen-induced contraction of ductus arteriosus isolated from the fetal rabbit. *Circ. Res.* **72**: 1218–1228.
- Nguyen, M., Camenisch, T., Snouwaert, J.N., Hicks, E., Coffman, T.M., Anderson, P.A., Malouf, N.N. and Koller, B.H. (1997). The prostaglandin receptor EP4 triggers remodelling of the

- cardiovascular system at birth. *Nature* **390**: 78–81.
- Rabinowitch, M. (1996). Cell-extracellular matrix interactions in the ductus arteriosus and perinatal pulmonary circulation. *Semin. Perinatol.* **20**: 531–541.
- Reeve, H.L., Tolarova, S., Nelson, D.P., Archer, S. and Weir, E.K. (2001). Redox control of oxygen sensing in the rabbit ductus arteriosus. *J. Physiol. (Lond.)* **533**: 253–261.
- Segi, E., Sugimoto, Y., Yamasaki, A., Aze, Y., Oida, H., Nishimura, T., Murata, T., Matsuoka, T., Ushikubi, F., Hirose, M., Tanaka, T., Yoshida, N., Narumiya, S. and Ichikawa, A. (1998). Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. *Biochem. Biophys. Res. Commun.* **246**: 7–12.
- Seidner, S.R., Chen, Y.Q., Oprysko, P.R., Mauray, F., Tse, M.M., Lin, E., Koch, C. and Clyman, R.I. (2001). Combined prostaglandin and nitric oxide inhibition produces anatomic remodeling and closure of the ductus arteriosus in the premature newborn baboon. *Pediatr. Res.* **50**: 365–373.
- Slomp, J., Gittenberger-de Groot, A.C., Glukhova, M.A., Conny van Munsteren, J., Kockx, M.M., Schwartz, S.M. and Koteliansky, V.E. (1997). Differentiation, dedifferentiation, and apoptosis of smooth muscle cells during the development of the human ductus arteriosus. *Arterioscler. Thromb. Vasc. Biol.* **17**: 1003–1009.
- Smith, G.C. (1998). The pharmacology of the ductus arteriosus. *Pharmacol. Rev.* **50**: 35–58.
- Smith, G.C. and McGrath, J.C. (1988). Indomethacin, but not oxygen tension, affects the sensitivity of isolated neonatal rabbit ductus arteriosus, but not aorta, to noradrenaline. *Cardiovasc. Res.* **22**: 910–915.
- Smith, G.C. and McGrath, J.C. (1993). Characterisation of the effect of oxygen tension on response of fetal rabbit ductus arteriosus to vasodilators. *Cardiovasc. Res.* **27**: 2205–2211.
- Smith, G.C. and McGrath, J.C. (1994). Interactions between indomethacin, noradrenaline and vasodilators in the fetal rabbit ductus arteriosus. *Br. J. Pharmacol.* **111**: 1245–1251.
- Tada, T., Wakabayashi, T., Nakao, Y., Ueki, R., Ogawa, Y., Inagawa, A., Shibata, T. and Kishimoto, H. (1985). Human ductus arteriosus. A histological study on the relation between ductal maturation and gestational age. *Acta Pathol. Jpn.* **35**: 23–34.
- Takahashi, Y., Roman, C., Chemtob, S., Tse, M.M., Lin, E., Heymann, M.A. and Clyman, R.I. (2000). Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo. *Am. J. Physiol.* **278**: R1496–R1505.
- Toyoshima, K., Takeda, A., Imamura, S., Nakanishi, T. and Momma, K. (2006). Constriction of the ductus arteriosus by selective inhibition of cyclooxygenase-1 and -2 in near-term and preterm fetal rats. *Prostaglandins Other. Lipid Mediat.* **79**: 34–42.
- Tristani-Firouzi, M., Reeve, H.L., Tolarova, S., Weir, E.K. and Archer, S.L. (1996). Oxygen-induced constriction of rabbit ductus arteriosus occurs via inhibition of a 4-aminopyridine-, voltage-sensitive potassium channel. *J. Clin. Invest.* **98**: 1959–1965.
- Trivedi, D.B., Sugimoto, Y. and Loftin, C.D. (2006). Attenuated cyclooxygenase-2 expression contributes to patent ductus arteriosus in preterm mice. *Pediatr. Res.* **60**: 669–674.
- Van Overmeire, B., Allegaert, K., Casaer, A., Debauche, C., Decaluwe, W., Jespers, A., Weyler, J., Harrewijn, I. and Langhendries, J.P. (2004). Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet* **364**: 1945–1949.
- Wu, G.R., Jing, S., Momma, K. and Nakanishi, T. (2001). The effect of vitamin A on contraction of the ductus arteriosus in fetal rat. *Pediatr. Res.* **49**: 747–754.
- Yokoyama, U., Minamisawa, S., Adachi-Akahane, S., Akaike, T., Naguro, I., Funakoshi, K., Iwamoto, M., Nakagome, M., Uemura, N., Hori, H., Yokota, S. and Ishikawa, Y. (2006a). Multiple transcripts of Ca²⁺ channel alpha1-subunits and a novel spliced variant of the alpha1C-subunit in rat ductus arteriosus. *Am. J. Physiol.* **290**: H1660–H1670.
- Yokoyama, U., Minamisawa, S., Quan, H., Akaike, T., Suzuki, S., Jin, M., Jiao, Q., Watanabe, M., Otsu, K., Iwasaki, S., Nishimaki, S., Sato, M. and Ishikawa, Y. (2008). Prostaglandin E2-activated Epac

promotes neointimal formation of the rat ductus arteriosus by a process distinct from that of cAMP-dependent protein kinase A. *J. Biol. Chem.* **283**: 28702-28709.

Yokoyama, U., Minamisawa, S., Quan, H., Ghatak, S., Akaike, T., Segi-Nishida, E., Iwasaki, S., Iwamoto, M., Misra, S., Tamura, K., Hori, H., Yokota, S., Toole, B.P., Sugimoto, Y. and Ishikawa, Y. (2006b). Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. *J. Clin. Invest.* **116**: 3026-3034.

Yokoyama, U., Sato, Y., Akaike, T., Ishida, S., Sawada, J., Nagao, T., Quan, H., Jin, M., Iwamoto, M., Yokota, S., Ishikawa, Y. and Minamisawa, S. (2007). Maternal vitamin A alters gene profiles and structural maturation of the rat ductus arteriosus. *Physiol. Genomics* **31**: 139-157.



Review

Accessory proteins for heterotrimeric G-protein: Implication in the cardiovascular system

Motohiko Sato*, Yoshihiro Ishikawa

Cardiovascular Research Institute, Yokohama City University, School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama 236-0004, Japan

Received 26 January 2009; received in revised form 11 March 2009; accepted 20 March 2009

Abstract

The G-protein signaling system plays an important role in controlling cellular responses to numerous hormones and neurotransmitters involved in homeostasis of the cardiovascular system. In addition to traditional determinants of G-protein signaling such as the G-protein-coupled receptor (GPCR), heterotrimeric G-proteins and effectors, accumulating data indicate the existence of entities that directly regulate the activation status of G-proteins independent of GPCR. To date, there have been a number of reports on accessory proteins that influence GDP dissociation, affect nucleotide exchange at the $G\alpha$ subunit, alter subunit interactions within heterotrimeric $G\alpha\beta\gamma$ independent of nucleotide exchange, or form complexes with $G\alpha$ or $G\beta\gamma$ independent of the typical $G\alpha\beta\gamma$ heterotrimer. Such proteins may provide an additional signal input to the G-protein signaling system in the absence of GPCR or may act as an alternative binding partner of G-protein subunits serving unknown roles of G-proteins in cells. Accumulating information suggests that accessory proteins for G-proteins are actually involved in the regulation of the signaling system to maintain homeostasis and the dynamic responses to physiological and pathological challenges. It is likely that alterations in signal processing may be achieved by the modulation of signal processing within the cell using accessory proteins for G-proteins. The loss of regulation of this system, leading to inappropriate activation or inactivation of G-protein signaling, is strongly implicated in various human diseases. In this review, we update current information and discuss different accessory proteins for heterotrimeric G-proteins in terms of their involvement in the regulation of the cardiovascular system. Such information may contribute to uncovering mechanisms underlying cardiovascular disease as well as the development of novel therapeutic approaches to human disease.

© 2009 Elsevier Ireland Ltd. All rights reserved.

Keywords: Heterotrimeric G-protein; Signal transduction; Activator of G-protein signaling (AGS); Regulator of G-protein signaling (RGS); Cardiovascular disease

Contents

1. Introduction	90
2. Guanine nucleotide exchange factors (GEFs) for $G\alpha$ subunit	91
2.1. Activator of G-protein signaling 1 (AGS1, DexRas1, and RASD1)	91
2.2. Growth-associated protein 43 (GAP43)	91
2.3. Phosphatidylethanolamine-binding protein (PBP)/Raf kinase inhibitor protein (RKIP)	91
2.4. Presenilin-1	92
2.5. Tubulin	92
3. Guanine nucleotide dissociation inhibitors (GDIs) for $G\alpha$ subunit	93
3.1. Activator of G-protein signaling 3 (AGS3)	93
4. GTPase-activating proteins (GAPs) for $G\alpha$ subunit	93
4.1. RGS4	93
4.2. RGS2	94

* Corresponding author. Tel.: +81 45 787 2575; fax: +81 45 788 1470.

E-mail address: motosato@yokohama-cu.ac.jp (M. Sato).

5.	Accessory proteins interact with subunits of G $\beta\gamma$	94
5.1.	Activator of G-protein signaling 8 (AGS8)	94
5.2.	Receptor for activated C kinase 1 (RACK1)	95
5.3.	Syntaxin 1A	95
5.4.	Phosducin and phosducin-like protein	95
6.	Conclusions and perspective	95
	Acknowledgements	96
	References	96

1. Introduction

Signal processing via heterotrimeric G-proteins is one of the most widely used systems for information transfer across the cell membrane. This system is essential for maintaining tissue homeostasis, but is also involved in the development of cardiac hypertrophy [1], remodeling of the heart [1], ischemic preconditioning [2,3], and angiogenesis [4]. In addition, many of the therapeutic interventions are used in the management of cardiovascular disease targeting G-protein signaling systems via cell surface G-protein-coupled receptors (GPCRs).

In this system, seven transmembrane domain GPCRs are activated by extracellular stimuli, such as hormones and neurotransmitters, inducing a conformational change in the G α subunit, and then catalyzing GDP release from G α (Fig. 1). Binding of GTP to G α destabilizes G $\alpha\beta\gamma$ complex, leading to a structural rearrangement of G α -GTP, G $\beta\gamma$ and the receptor. This is followed by G α -GTP disassociation from the receptor and G $\beta\gamma$. Both subunits, G α -GTP and G $\beta\gamma$, stimulate distinct downstream effector molecules including adenylyl cyclases, phospholipases, ion channels, and protein kinases [5–7]. The activation of the signaling pathway is terminated when G α hydrolyzes GTP to GDP by its intrinsic guanosine triphosphatase (GTPase) activity; it then reassociates with G $\beta\gamma$, thus completing the cycle. Reassociation of G $\beta\gamma$




Fig. 1. Schematic diagram indicating G-protein activation/deactivation cycle and influences of G α regulatory protein. GEF: guanine nucleotide exchange factor; GDI: guanine nucleotide dissociation inhibitor; GAP: GTPase-activating protein; GPCR: G-protein-coupled receptor.

Table 1

Abbreviations.

AGS, activator of G-protein signaling
ERK, extracellular signal-regulated kinase
GAP, GTPase-activating protein
GDI, guanine nucleotide dissociation inhibitor
GEF, guanine nucleotide exchange factor
GDP, guanosine-5'-diphosphate
GIRK, G-protein-activated inwardly rectifying potassium channel
GPCR, G-protein-coupled receptor
GPR, G-protein regulatory
GRK, G-protein-coupled receptor kinase
GTP, guanosine-5'-triphosphate
GTP γ S, guanosine-5'-O-(3-thiotriphosphate)
HSP-90, heat shock protein 90
KATP, ATP-sensitive potassium
MAP, mitogen-activated protein
MEK, MAP/ERK kinase
NG-GPA, NG108-15 G-protein activator
NMDA, N-methyl-D-aspartate
Pcp2, Purkinje cell protein-2
PBP, phosphatidylethanolamine-binding protein
RACK1, receptor for activated C kinase 1
RGS, regulator of G-protein signaling
Ric, resistance to inhibitors of cholinesterase
RKIP, Raf-1 kinase inhibitor protein
siRNA, small interfering RNA
SNARE, soluble N-ethylmaleimide-sensitive factor attachment protein receptor

with G α -GDP terminates interactions of effector molecules. G $\beta\gamma$ facilitates the coupling of G α to GPCR and also acts as a guanine nucleotide inhibitor (GDI) for G α -GDP, slowing spontaneous exchange of GDP for GTP (Table 1).

These events are dynamically regulated to optimize signal specificity, maximize signal efficiency and integrate diverse stimuli. As a consequence of this central role in signal integration, the subtle adaptations or maladaptations that occur in response to both physiological and pathophysiological challenges can play a key role in the manner in which the effector cell responds to such challenges. Regulations of the G-protein system include the segregation of specific signaling molecules in cell microdomains, receptor phosphorylation and internalization, and crosstalk between signaling pathways. In addition to these, a number of proteins that regulate the basal activation state of G-proteins independently of cell surface GPCR have been discovered. Such accessory proteins influence the activation or deactivation of the G α subunit and alter subunit interactions within heterotrimeric G $\alpha\beta\gamma$ independent of nucleotide exchange, or form complexes with

$G\alpha$ or $G\beta\gamma$ independent of the typical $G\alpha\beta\gamma$ heterotrimer. Accessory proteins for G-proteins may provide an additional signal input to the G-protein signaling system in the absence of GPCR or may act as an alternative binding partner of G-protein subunits serving unknown roles of G-proteins in cells. In previous work, we evolved the observation of such accessory proteins and tuning of the signaling system concerned based on cell-specific differences [8,9] and the subsequent biochemical characterization of such differences [9–12]. We later addressed the impact of accessory proteins in terms of system adaptation of the GPCR system [13] and identified novel accessory proteins for G-proteins induced in the myocardium in response to transient ischemia [14].

An adaptation of the signaling system is critical for maintaining homeostasis and the dynamic responses to physiological and pathological challenges. It is likely that subtle alterations in signal processing may be achieved by discrete modulation of signal processing within the cell using accessory proteins for G-proteins. Current information suggests that accessory proteins for G-proteins are actually involved in the regulation of the signaling system for maintaining homeostasis and the dynamic responses to physiological and pathological challenges. The loss of regulation of this system, leading to inappropriate activation or inactivation of G-protein signaling, is strongly implicated in various human diseases.

In this review, we update current information and discuss various accessory proteins for heterotrimeric G-proteins in terms of their involvement in the regulation of the cardiovascular system (Table 2). Such information may contribute to uncovering the mechanisms underlying cardiovascular disease as well as the development of a novel therapeutic approach to human disease.

2. Guanine nucleotide exchange factors (GEFs) for $G\alpha$ subunit

The first class of accessory proteins facilitates guanine nucleotide exchange of $G\alpha$ subunits such as activated G-protein-coupled receptors. Proteins have been identified as nonreceptor GEFs that increase GTP γ S binding to the $G\alpha$ subunit similar to activated GPCR, and include GAP43 [15,16], NG-GPA [8,9], β -APP [17], presenilin I [18], AGS1 [19–23], PBP/RKIP [24–28], and Ric-8 [29]. Among 16 of the $G\alpha$ genes identified [30,31], most of them preferentially activate the $G\alpha_i$ family; however, Ric-8A can also activate $G\alpha_q$ in vitro [29]. Although the regulation of GEF and its physiological relevance are not completely understood at present, its potential association with cardiovascular disease has been reported in several proteins (Table 2).

2.1. Activator of G-protein signaling 1 (AGS1, *DexRas1*, and *RASD1*)

AGS1 was initially discovered as dexametasone-inducible, ras-related cDNA (*DexRas*) in mouse corticotroph

cells [21]. AGS1 is a member of the Ras family of monomeric GTPases which is most closely related to Rhes (60% amino acid identity), a Ras-related protein with unique insert regions [32,33]. Purified AGS1 directly binds to $G\alpha_i$, and increases GTP γ S binding to purified $G\alpha_{i1}$ and $G\alpha_{i2}$ in vitro [22].

In mammalian cells, transfected AGS1 activates the Erk1/2 pathway without receptor stimulation [22]. AGS1 also inhibits cAMP accumulation in response to forskolin or a constitutive active $G\alpha_s$ [34], which is also consistent with the regulation of $G\alpha_i$ by AGS1, indicating the function of AGS1 as a direct $G\alpha$ activator. However, when transiently co-transfected with a $G\alpha_i$ -coupled receptor, AGS1 blocks the downstream signaling of the agonist-stimulated receptor, as well as the receptor-mediated heterologous sensitization of adenylyl cyclase [35].

In human tissues, AGS1 is highly enriched in heart, brain, liver, skeletal muscle and bone marrow, with lower expression in pancreas, kidney, thymus, lung and placenta [36,37]. AGS1 expression is induced by various stimuli related to stress. Moreover, AGS1 expression is up-regulated in cultured cells following glucocorticoid treatment [21] and in whole animals following severe blood loss [38], suggesting that AGS1 plays a role in mediating the stress response. The disruption of AGS1 in mice suggests its importance in the signaling of the NMDA-mediated circadian cycle [39].

A comprehensive concept of AGS1 function in the context of the whole signaling system is still being developed.

2.2. Growth-associated protein 43 (GAP43)

GAP43 enriched in the neuronal growth cone plays an important role during development and axonal regeneration. GAP43 increases the rate of GDP dissociation and GTP γ S association to purified brain heterotrimer G-proteins and purified $G\alpha_o$ free of $G\beta\gamma$ [15,16]. In oocytes, GAP43 enhanced GPCR signaling in response to an agonist and was able to cause a transient current flow without receptor activation [40]. GAP43 is involved in the innervation of cardiomyocytes and left stellate ganglions [41]. The upregulation of GAP43 was reported in several experimental models, including myocardial infarction [41,42] and right ventricular hypertrophy [43].

2.3. Phosphatidylethanolamine-binding protein (PBP)/Raf kinase inhibitor protein (RKIP)

PBP or RKIP is a 23-kDa soluble protein that inhibits the activation of MEK [24,25] by RAF1 and also blocks GRK2 activity [26], suggesting a role in signal crosstalk in cells. PBP/RKIP facilitates binding of GTP γ S to purified $G\alpha_{i1}$, and appears to enhance $G\alpha_{i/o}$ -mediated signaling in vivo [28]. Lorenz et al. demonstrated that PKC activation following GPCR activation triggered RKIP dissociation from Raf-1 to associate with GRK2 [26]. Thus, the GPCR signal is enhanced both by removing an inhibitor from Raf-1 and by blocking receptor internalization via GRK2.

Table 2
 Accessory proteins for heterotrimeric G-protein involved in the regulation of cardiovascular system.

Proteins	Function on G-protein	Association with cardiovascular system	References
Guanine nucleotide exchange factors (GEFs) for $G\alpha$ subunit			
AGS1	GEF for $G\alpha_i$	Relative high level expression in human heart; up-regulated in response to biological stress	[19–23,35–39]
GAP-43	GEF for brain G-protein and $G\alpha_o$	Enriched in stellate ganglion; upregulation in myocardial infarction and right ventricular hypertrophy	[15,16,40–43]
PBP/RKIP	GEF for purified $G\alpha_{i1}$	Involved in β -adrenergic signaling and contractility of cardiomyocyte	[24–28]
Presenilin	GEF and GAP for $G\alpha_o$	Critical factor for cardiac development and familial DCM	[18,44–46]
Tubulin	Transactivate $G\alpha$ subunit, interact with $G\beta\gamma$ subunit	Multiple roles including protein sorting; microtubule regulation	[47–52]
Guanine nucleotide dissociation inhibitors (GDIs) for $G\alpha$ subunit			
AGS3	GDI for $G\alpha_{i/o}$, stabilize $G\alpha$ -GDP complex	Short variant expressed in the heart; AGS3 null mice exhibited lower arterial pressure and an enhanced gain of the baroreceptor reflex	[13,32,33,55–56]
Caveolin	Inhibit GTPase activity and GTP γ S binding to $G\alpha_o$. Interact with $G\alpha_{i2}$	Involved in various signaling system via its scaffolding function	[111–114]
GTPase-activating proteins (GAPs) for $G\alpha$ subunit			
RGS2	GAP for $G\alpha_q \gg G\alpha_{i/o}$	Deletion of RGS2 caused strong hypertension in mice	[70,76–82]
RGS4	GAP for $G\alpha_{i/o}$, $G\alpha_q$	RGS4 overexpressing mice delayed hypertrophy in response to the pressure stress or $G\alpha_q$ pathway stimulation	[66,69,71–75]
Hax-1	Enhances $G\alpha_{i3}$ -mediated Rac activity	Inhibits apoptosis of adult cardiomyocyte through interaction with caspase-9	[115]
Accessory proteins interact with $G\beta\gamma$ subunits			
AGS8	Interact with $G\beta\gamma$ subunit	Identified in repetitive transient ischemia model of rat heart; increased expression in response to ischemia/hypoxia	[14,90]
Phosducin and phosducin-like protein	Interact with $G\beta\gamma$ subunit	Expression in the heart; overexpression of part of phosducin improved contractivity of failing heart	[102–110]
RACK1	Interact with $G\beta\gamma$ subunit	Suggested involvement in reduced contractility of senescent cardiomyocyte	[92–96]
Syntaxin1	Interact with $G\beta\gamma$ subunit	Modulate K^+ and Ca^{2+} channel activity; involvement in atrial natriuretic peptide release from cardiomyocyte	[97–101]
GRK2	Interact with $G\beta\gamma$ subunit	Regulation of cell surface GPCR	[116,117]
Others			
HSP-90	Alter $G\alpha_{i2}$ signaling	Involved in multiple signaling cascades via chaperone function	[118]

A physiologic role for this mechanism was shown in cardiomyocytes in which the downregulation of RKIP restrains β -adrenergic signaling and contractile activity. Thus, the relative importance of these different actions of PBP/RKIP needs to be addressed.

2.4. Presenilin-1

Presenilin-1 is the gene responsible for the development of early-onset familial Alzheimer's disease and is involved in multiple cellular events [44]. The C-terminus of presenilin directly interacts with and enhances both GTP γ S binding and

GTP hydrolysis of $G\alpha_o$ [18]. Presenilin-1 is also expressed in the heart and is critical for cardiac development [45]. Li et al. reported familial DCM and heart failure associated with missense mutation of presenilin [46]. The role of the interaction of these proteins with G-proteins in the development of heart failure is not well understood at present.

2.5. Tubulin

Tubulin activates the $G\alpha$ subunit by different mechanisms, and thus it increases GTP binding to $G\alpha$ subunits by the transfer of GTP bound on tubulin to the GDP bound on

G α [47–51]. Tubulin has also been reported to interact with GPCR and G $\beta\gamma$ [52]. From its functions, tubulin has been suggested to have multiple roles in trafficking, G-protein activation, and the control of microtubule dynamics [52]. Furthermore, tubulin and G-protein interaction may influence microtubule polymerization and alter cardiomyocyte architecture.

3. Guanine nucleotide dissociation inhibitors (GDIs) for G α subunit

The second class of accessory protein is a group of guanine nucleotide dissociation inhibitors (GDIs). The majority of this subgroup of accessory proteins shares a common structural feature termed the G-protein regulatory (GPR) or GoLoco motif [32,33,53]. The GPR motif is a 20–25 amino acid cassette that serves as a docking site for G $\alpha_{i/o}$ and G α_t . The interaction of GPR motifs with G $\alpha_{i/o}$ stabilizes the GDP-bound conformation of G α and interferes with G $\beta\gamma$ for binding to G α_i , which results in inhibition of G α -mediated signaling and prolongation of G $\beta\gamma$ -mediated signaling. The GPR motif is found in AGS3 (GPSM1), LGN (GPSM2), AGS4 (GPSM3), Purkinje cell protein-2 (Pcp2)/L7, WAVE-1 and the GTPase-activating proteins RGS12, RGS14, RAP1GAPI (partial GPR motif), and Rap1GAPII [32,33,53]. The GPR proteins are also known as crucial players in asymmetric cell division during embryogenesis [54].

3.1. Activator of G-protein signaling 3 (AGS3)

AGS3 (GPSM1) is one of the proteins extensively studied in GDIs for G α subunit. This protein was identified as a receptor-independent activator of G-protein signaling in a yeast-based functional screen of mammalian cDNAs. AGS3-LONG is a 650 amino acid protein containing 7 tetratricopeptide repeats as well as 4 GPR motifs, and is preferentially expressed in the brain. AGS3 has a short form enriched in the heart lacking the tetratricopeptide repeat motif domains and contains only three GPR motifs [55]. The impact of AGS3-SHORT in signal integration in cells was investigated in the sensitization of adenylyl cyclase. This sensitization is known as a transient enhancement of the activity of adenylyl cyclase following sustained stimulation of G α_i -coupled receptors, and as an example of an adaptive response of cells [56,57]. The sensitization of G α_s regulation of adenylyl cyclase observed with sustained activation of G α_i -coupled GPCR was blocked by the overexpression of heart-type AGS3 (AGS3-SHORT) in CHO cells [13]. This observation was associated with an increase in the stability of the G α_i subunit in the membrane. Interventions against AGS3 utilizing GPR-related components indicated that AGS3 also plays an important role in adaptive neuronal events associated with the drug-seeking behavior and locomotor sensitization following cocaine withdrawal [58,59]. These data suggested that AGS3 and GPR proteins

influenced the adaptation process of the G-protein signaling system.

Recently, Lanier's group carried out an initial characterization of AGS3 null mice [60]. In these mice, the full-length AGS3 was disrupted, but a short variant form of AGS3 was still expressed in the heart. Interesting alterations were observed in the regulation of blood pressure and metabolic functions in AGS3 null mice. Thus, the mean arterial pressure was significantly lower in AGS3 null mice, and its diurnal variations were reduced. Moreover, AGS3 null mice showed enhanced gain of the baroreceptor reflex. Altered vascular control was also observed in terms of the suppression of recovery of arterial pressure following administration of sodium nitroprusside. In the analysis of metabolic homeostasis, AGS3 null mice exhibited a lean phenotype, reduced fat mass and increased nocturnal energy expenditure. The first observation of a genetically modified animal of AGS3 suggests the potential of AGS3 and perhaps other GPR proteins as a therapeutic target in human disease.

4. GTPase-activating proteins (GAPs) for G α subunit

The majority of proteins of this group share 120–130 amino acids of the regulator of G-protein signaling (RGS) homology domain, which mediates the GTPase-accelerating activity at G α subunits [61,62]. At least 30 mammalian proteins are known to share an RGS or RGS-like domain [63,64]. Most of the RGS proteins are GAPs for G $\alpha_{i/o}$ and G $\alpha_{q/11}$ family members with some exceptions for GAPs for either G $\alpha_{12/13}$ or G α_s family members [64,65]. The change in the expression of RGS proteins in human heart failure has also been reported. Mittmann et al. indicated an increase in RGS4 mRNA but no change in RGS2 or RGS3 in the myocardium from terminally failing human hearts with dilated or ischemic cardiomyopathy [66], whereas Owen et al. found an apparent upregulation of RGS3 and RGS4 proteins and mRNA in end-stage failing hearts of humans [67]. Takeishi et al. also identified an apparent decrease of RGS2 protein in human failing heart following treatment with left ventricular assist device [68]. Although these results which might reflect the background of the patients were not consistent, alterations in RGS2, RGS3 and RGS4 expression suggested their potential to alter cardiovascular pathophysiology. Among the RGS protein families, the physiological roles of RGS2 and RGS4 in the cardiovascular system were extensively studied in mice deficient for RGS2 [69] or overexpressing RGS4 [70].

4.1. RGS4

RGS4 has a GAP activity for G $\alpha_{i/o}$ and G α_q and appears to negatively regulate signaling events mediated by G α subunits. Its association with schizophrenia has also been reported in some populations [71–73]. On the other hand, the role of RGS4 in cardiovascular function was previously examined utilizing transgenic mice overexpressing RGS4

[70]. The overexpression of RGS4 did not affect basal cardiac function or chronotropic response to dobutamine, but significantly reduced the ability of the heart to adapt to an increase in cardiac afterload induced by transverse aortic constriction. In cardiomyocytes, the overexpression of RGS4 inhibited phenylephrine- and endothelin-1-induced hypertrophy or contraction [66,74]. The co-overexpression of RGS4 and $G\alpha_q$ in transgenic mice delayed the $G\alpha_q$ -mediated onset of cardiac hypertrophy, which exhibits a phenotype similar to human cardiac hypertrophy [75]. The increase of RGS4 in a failing heart may decrease contractile response; however, this increase reduces the adverse effect of $G\alpha_q$ signaling. At present, the overall direction toward protection of the heart by RGS4 remains controversial.

4.2. RGS2

RGS2 has unique binding and some forms of selectivity for $G\alpha_{q/11}$ rather than for $G\alpha_i$ [76,77]. It appears to attenuate signaling events mediated by $G\alpha_{q/11}$ -coupled receptor, including vasoconstriction and cardiac hypertrophy [69,76,78]. It has also been shown that *rgs2*^{+/-} and *rgs2*^{-/-} mice exhibit a similar and strong hypertensive phenotype, suggesting that both copies of the gene are essential for normal cardiovascular function. Further analysis suggested that this phenotype may be attributed to enhanced and/or prolonged vascular contractile responses to GPCR stimulation [69,79].

The overexpression of RGS2 in cardiomyocytes eliminated any increase in cell size and genetic markers of hypertrophy in response to α_1 -adrenergic stimulation [80,81]. A recent study found RGS2 to be selectively down-regulated during the early onset of cardiac hypertrophy with enhanced $G\alpha_{q/11}$ signaling [82]. siRNA-mediated RGS2 knockdown increased phenylephrine- and endothelin-1-induced PLC β stimulation and exacerbated the hypertrophic effect [82]. Interestingly, no overt changes were observed in the cardiac function of *rgs2*^{-/-} mice up to 6 months of age [69]. These lines of evidence implied a beneficial effect of RGS2 in protecting the heart, although more studies are needed to clarify the role of RGS2 in hypertrophy-associated GPCR signals.

5. Accessory proteins interact with subunits of $G\beta\gamma$

There are 5 $G\beta$ and 12 $G\gamma$ subunits reported in humans and mice, offering potential of a large diversity of combinations of $G\beta\gamma$ dimers [6,30]. $G\beta_{1-4}$ share 82–92% homology with each other and $G\beta_5$ has approximately 50% divergent homology from others [6,30]. In contrast to the $G\beta$ subunit, $G\gamma$ shares only 15–30% sequence identity within subunits [6,30]. The $G\beta_5$ subunit is unique since it can form a unique complex with RGS7 apart from the gamma subunit. Other RGS proteins containing the $G\gamma$ -like (GGL) domain, namely, RGS6, RGS7, RGS9, and RGS11 are also predicted to be able to assemble with $G\beta_5$ [83–85]. Although $G\beta_5$ is pref-

erentially expressed in neuronal systems, a relatively higher expression in the heart was observed in humans than in mice [86]. However, the functional and/or physiological roles of this interesting complex are still not clear.

$G\beta$ subunit and $G\gamma$ subunit are tightly associated and usually act as a heterodimer. It was once considered that the $G\beta\gamma$ subunit inhibited the guanine nucleotide exchange of $G\alpha$ and terminated the G-protein signal by sequestering $G\alpha$ subunits. However, it is now known that $G\beta\gamma$ regulates many signaling molecules, including G-protein-activated inwardly rectifying potassium channel (GIRK), Ca channels, PLC β_2 and β_3 , PLC ϵ , and GRK2 [6,7]. Interestingly, mutational and structural studies have indicated that effector proteins and the $G\alpha$ subunit share an overlapping interface on the surface of $G\beta\gamma$ [7,87]. The $G\beta$ subunit does not have a catalytic site, and does not change its conformation when it dissociates from the $G\alpha$ subunit on activation of a heterotrimer. Thus, the activation of $G\beta\gamma$ -mediated signaling is initiated by protein–protein interaction of $G\beta\gamma$ without sharing the interface for signal transduction.

Number of $G\beta\gamma$ -interacting proteins continues to increase. Because $G\beta\gamma$ -interacting proteins share a common region of the surface, they would cover up and inhibit the $G\beta\gamma$ signal to other molecules. Thus, the binding of $G\beta\gamma$ -interacting proteins to this sharing site is principally expected to exclude interaction of other proteins, resulting in the shutdown of $G\beta\gamma$ signaling as $G\alpha$ does. Recently, Bonacci et al. have developed small molecules targeting the sharing interface of $G\beta\gamma$ and have also identified a compound selectively altering the $G\beta\gamma$ signaling pathway in cells [14,88].

5.1. Activator of G-protein signaling 8 (AGS8)

AGS8 was isolated utilizing a yeast-based functional screen expressing human $G\alpha$ in place of the yeast $G\alpha$ from a cDNA library generated from a rat model of repetitive transient ischemia of the heart [14]. In this model, rat hearts were subjected to repetitive transient ischemia by the inflation of an implanted pneumatic snare around the proximal left anterior descending coronary artery (40 s occlusion, 20 min interval, 8 h/day) that induced coronary collateral growth in 2 weeks [89].

AGS8 (GeneBank accession # DQ256268) encodes an uncharacterized 1730 amino acid protein (K1AA1866, FNDC1 in humans) with 4 fibronectin-type III domains, 3 at the N-terminus and 1 C-terminal [14]. The amount of AGS8 mRNA was increased in the ischemic area of left ventricle by 3.5-fold compared with the non-ischemic area; however, this increase was not induced in cardiac hypertrophy or heart failure, suggesting a specific role of AGS8 in the signaling processes underlying ischemia [14]. Incidentally, hypoxic treatment of adult ventricular cardiomyocytes up-regulated AGS8 mRNA by 8-fold. This increase was not observed in cultures of aortic endothelial cells, aortic vascular smooth muscle cells or cardiac fibroblasts. Protein interaction assays with GST-AGS8 and purified G-protein subunits or brain

lysates indicated direct binding of AGS8 to G $\beta\gamma$ [14]. Interestingly, subsequent studies suggested that the interaction of AGS8 with G $\beta\gamma$ occurred in a manner that did not alter the regulation of the effector PLC- β_2 by G $\beta\gamma$. The AGS8 binding site on the G $\beta\gamma$ subunit appears to reside at the common interface of G β overlapping with PLC- β_2 and the G α subunit [7,90]. This observation suggested, in line with expectations, that the mechanism of G $\beta\gamma$ interaction to other molecules might be more complex. An alternative mode of G $\beta\gamma$ interaction and the formation of signaling components are postulated [7,90].

AGS8 serves as an ischemia-inducible binding partner for G $\beta\gamma$ in cardiomyocytes providing an unexpected mode of signal input to the G-protein system. Such mechanisms of signal regulation may provide intrinsic cues for the adaptation of the heart to ischemia.

5.2. Receptor for activated C kinase 1 (RACK1)

G β belongs to a large family of WD40 repeat proteins [91] and interacts with other WD40 proteins, such as the receptor for activated C kinase 1 (RACK1) [92]. RACK1 shares 57% amino acid similarity with G β_1 lacking N-terminal extension for binding the G γ subunit, and usually does not interact with the G α subunit [93].

RACK1 inhibited the G $\beta\gamma$ -mediated activation of phospholipase C β_2 and adenylyl cyclase, whereas it showed no obvious effect on G $\beta\gamma$ -mediated chemotaxis, MAP kinase activation or G α -mediated signaling. The association of G $\beta\gamma$ with RACK1 induces the translocation of RACK1 from cytosol to the plasma membrane. This has been suggested as a mechanism for recruiting PKC and other RACK1-binding proteins to the plasma membrane [93,94]. PKC recruitment to G-protein-coupled receptors by G $\beta\gamma$ /RACK1 can contribute to the efficient modulation of signaling by PKC. Furthermore, the role of the translocation of RACK1 on α_1 -adrenergic-mediated myocardial contraction was investigated in senescent rat hearts. It was suggested that the decreased level of RACKs in the senescent myocardium was involved in an impairment of the translocation of PKC α and PKC ϵ following α_1 -adrenergic receptor stimulation, resulting in a defective α_1 -adrenergic-receptor-mediated contraction in aged rat hearts [95]. The influence of RACK1 was also investigated in H9C2 stably expressing RACK1. RACK1 influenced cell size, cell survival under oxidative stress, adhesion, and migration of H9C2 cells [96].

5.3. Syntaxin 1A

Syntaxin 1A is a protein of the presynaptic vesicle release complex. Syntaxin 1A has been shown to directly interact with the G $\beta\gamma$ subunit and to modulate N-type calcium channels expressed in tsA-201 (HEK) cells [97,98]. In freshly isolated cardiomyocytes, inhibition of syntaxin 1A on the ATP-sensitive potassium channel (KATP channel, Kir6.2/SUR2A)

was also demonstrated, which may serve as a “brake” to temper the fluctuation of low pH-induced KATP channel opening that could induce fatal re-entrant arrhythmias [99]. Syntaxin 1 may also play a role in the secretion of atrial natriuretic peptide in adult cardiac myocytes as in the soluble N-ethylmaleimide-sensitive fusion factor attachment protein receptor (SNARE) complex [100,101]. Although the roles of G $\beta\gamma$ in these functions are not fully identified, an interaction of syntaxin 1A with G $\beta\gamma$ has potentials to be involved.

5.4. Phosducin and phosducin-like protein

Phosducin is a 33-kDa cytosolic regulator of G-protein signaling, which was found in the retina and pineal gland as well as many other tissues including heart [102–104]. Phosducin-like protein, a protein sharing extensive amino acid sequence homology with phosducin, is also expressed in heart [105,106]. In the retina, phosducin interferes with the reassociation of G α_t and G $\beta\gamma$ following light-mediated G-protein activation. In an experimental system, phosducin and phosducin-like protein bound G $\beta\gamma$ [107–109] and effectively impeded G $\beta\gamma$ -mediated signaling. Although the overexpression of one part of phosducin improved the contractility of cardiomyocytes and a failing heart, its physiological relevance needs to be further determined [110].

6. Conclusions and perspective

A number of accessory proteins for heterotrimeric G-proteins have been identified in recent years. Each of them has unique selectivity for subunits and functions in the G-protein activation cycle or subunit association. Accumulating data indicates the involvement of these proteins in the regulation of the cardiovascular system. Also, the impact of several such proteins was compelling and has been characterized. However, the effects of many of these proteins on the cardiovascular system are described from their other functional properties rather than from their function on G-proteins.

The challenges facing this research field are to determine how these accessory proteins integrate into various signaling systems and to identify the role of the interaction of G-proteins to “other” functional properties of each accessory protein. Further precise information is expected to be elucidated on the basic mechanisms of accessory proteins on the activation of G-proteins as well as their role in G-protein-mediated signaling, especially in the face of physiological stress.

All these issues have important implications in relation to basic cell biology as well as to the understanding of the physiological response of the cardiovascular system to maintain homeostasis against stress. Further information will thus contribute to the development of novel therapeutics for human disease.

Acknowledgements

This review article was supported in part from Grant-in-Aid for Scientific Research (C) 18599006 and 20590212 (to M.S.), Yokohama Foundation for Advancement of Medical Science (to M.S.), the grant for Strategic Research Project K18017 and K19021 of Yokohama City University, Japan (to M.S.) and the Ministry of Education, Science, Sports and Culture of Japan (to Y.I.). M.S. is greatly appreciative for support provided by Takeda Science Foundation, NOVARTIS Foundation (Japan) for the Promotion of Science, Mitsubishi Pharma Research Foundation, The Ichiro Kanehara Foundation and Mochida Memorial Foundation for Medical and Pharmaceutical Research. Y.I. is greatly appreciative for support provided by Takeda Science Foundation and Kitsuen Research Foundation.

References

- [1] N.C. Salazar, J. Chen, H.A. Rockman, Cardiac GPCRs: GPCR signaling in healthy and failing hearts, *Biochim. Biophys. Acta* 1768 (2007) 1006–1018.
- [2] G.S. Liu, J. Thornton, D.M. Van Winkle, A.W. Stanley, R.A. Olsson, J.M. Downey, Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart, *Circulation* 84 (1991) 350–356.
- [3] M. Kitakaze, M. Hori, S. Takashima, H. Sato, M. Inoue, T. Kamada, Ischemic preconditioning increases adenosine release and 5'-nucleotidase activity during myocardial ischemia and reperfusion in dogs. Implications for myocardial salvage, *Circulation* 87 (1993) 208–215.
- [4] Y. Liu, R. Wada, T. Yamashita, Y. Mi, C.X. Deng, J.P. Hobson, H.M. Rosenfeldt, V.E. Nava, S.S. Chae, M.J. Lee, et al., Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation, *J. Clin. Invest.* 106 (2000) 951–961.
- [5] Y. Ishikawa, C.J. Homey, The adenylyl cyclases as integrators of transmembrane signal transduction, *Circ. Res.* 80 (1997) 297–304.
- [6] L. Birnbaumer, Expansion of signal transduction by G proteins. The second 15 years or so: from 3 to 16 alpha subunits plus betagamma dimers, *Biochim. Biophys. Acta* 1768 (2007) 772–793.
- [7] A.V. Smrcka, G protein betagamma subunits: central mediators of G protein-coupled receptor signaling, *Cell. Mol. Life Sci.* 65 (2008) 2191–2214.
- [8] M. Sato, R. Kataoka, J. Dingus, M. Wilcox, J.D. Hildebrandt, S.M. Lanier, Factors determining specificity of signal transduction by G-protein-coupled receptors. Regulation of signal transfer from receptor to G-protein, *J. Biol. Chem.* 270 (1995) 15269–15276.
- [9] M. Sato, C. Ribas, J.D. Hildebrandt, S.M. Lanier, Characterization of a G-protein activator in the neuroblastoma-glioma cell hybrid NG108-15, *J. Biol. Chem.* 271 (1996) 30052–30060.
- [10] A. Marjamaki, M. Sato, R. Bouet-Alard, Q. Yang, I. Limon-Boulez, C. Legrand, S.M. Lanier, Factors determining the specificity of signal transduction by guanine nucleotide-binding protein-coupled receptors. Integration of stimulatory and inhibitory input to the effector adenylyl cyclase, *J. Biol. Chem.* 272 (1997) 16466–16473.
- [11] J. Zhang, M. Sato, E. Duzic, S.W. Kubalak, S.M. Lanier, J.G. Webb, Adenylyl cyclase isoforms and vasopressin enhancement of agonist-stimulated cAMP in vascular smooth muscle cells, *Am. J. Physiol.* 273 (1997) H971–980.
- [12] C. Ribas, A. Takesono, M. Sato, J.D. Hildebrandt, S.M. Lanier, Pertussis toxin-insensitive activation of the heterotrimeric G-proteins Gi/Go by the NG108-15 G-protein activator, *J. Biol. Chem.* 277 (2002) 50223–50225.
- [13] M. Sato, T.W. Gettys, S.M. Lanier, AGS3 and signal integration by Galpha(s)- and Galpha(i)-coupled receptors: AGS3 blocks the sensitization of adenylyl cyclase following prolonged stimulation of a Galpha(i)-coupled receptor by influencing processing of Galpha(i), *J. Biol. Chem.* 279 (2004) 13375–13382.
- [14] M. Sato, M.J. Cismowski, E. Toyota, A.V. Smrcka, P.A. Lucchesi, W.M. Chilian, S.M. Lanier, Identification of a receptor-independent activator of G protein signaling (AGS8) in ischemic heart and its interaction with Gbetagamma, *Proc. Natl. Acad. Sci. U.S.A.* 103 (2006) 797–802.
- [15] S.M. Strittmatter, D. Valenzuela, T.E. Kennedy, E.J. Neer, M.C. Fishman, G0 is a major growth cone protein subject to regulation by GAP-43, *Nature* 344 (1990) 836–841.
- [16] S.M. Strittmatter, D. Valenzuela, Y. Sudo, M.E. Linder, M.C. Fishman, An intracellular guanine nucleotide release protein for G0. GAP-43 stimulates isolated alpha subunits by a novel mechanism, *J. Biol. Chem.* 266 (1991) 22465–22471.
- [17] I. Nishimoto, T. Okamoto, Y. Matsuura, S. Takahashi, Y. Murayama, E. Ogata, Alzheimer amyloid protein precursor complexes with brain GTP-binding protein G(o), *Nature* 362 (1993) 75–79.
- [18] A. Smine, X. Xu, K. Nishiyama, T. Katada, P. Gambetti, S.P. Yadav, X. Wu, Y.C. Shi, S. Yasuhara, V. Homburger, et al., Regulation of brain G-protein go by Alzheimer's disease gene presenilin-1, *J. Biol. Chem.* 273 (1998) 16281–16288.
- [19] M.J. Cismowski, A. Takesono, C. Ma, J.S. Lizano, X. Xie, H. Fuernkranz, S.M. Lanier, E. Duzic, Genetic screens in yeast to identify mammalian nonreceptor modulators of G-protein signaling, *Nat. Biotechnol.* 17 (1999) 878–883.
- [20] A. Takesono, M.J. Cismowski, C. Ribas, M. Bernad, P. Chung, S. Hazard 3rd, E. Duzic, S.M. Lanier, Receptor-independent activators of heterotrimeric G-protein signaling pathways, *J. Biol. Chem.* 274 (1999) 33202–33205.
- [21] R.J. Kemppainen, E.N. Behrend, Dexamethasone rapidly induces a novel ras superfamily member-related gene in AtT-20 cells, *J. Biol. Chem.* 273 (1998) 3129–3131.
- [22] M.J. Cismowski, C. Ma, C. Ribas, X. Xie, M. Spruyt, J.S. Lizano, S.M. Lanier, E. Duzic, Activation of heterotrimeric G-protein signaling by a ras-related protein. Implications for signal integration, *J. Biol. Chem.* 275 (2000) 23421–23424.
- [23] T.E. Graham, T.A. Key, K. Kilpatrick, R.I. Dorin, Dexas1/AGS-1, a steroid hormone-induced guanosine triphosphate-binding protein, inhibits 3',5'-cyclic adenosine monophosphate-stimulated secretion in AtT-20 corticotroph cells, *Endocrinology* 142 (2001) 2631–2640.
- [24] K. Yeung, T. Seitz, S. Li, P. Janosch, B. McFerran, C. Kaiser, F. Fee, K.D. Katsanakis, D.W. Rose, H. Mischak, et al., Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP, *Nature* 401 (1999) 173–177.
- [25] K. Yeung, P. Janosch, B. McFerran, D.W. Rose, H. Mischak, J.M. Sedivy, W. Kolch, Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein, *Mol. Cell. Biol.* 20 (2000) 3079–3085.
- [26] K. Lorenz, M.J. Lohse, U. Quitterer, Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2, *Nature* 426 (2003) 574–579.
- [27] D.K. Grandy, E. Hanneman, J. Bunzow, M. Shih, C.A. Machida, J.M. Bidlack, O. Civelli, Purification, cloning, and tissue distribution of a 23-kDa rat protein isolated by morphine affinity chromatography, *Mol. Endocrinol.* 4 (1990) 1370–1376.
- [28] T. Krosiak, T. Koch, E. Kahl, V. Hollt, Human phosphatidylethanolamine-binding protein facilitates heterotrimeric G protein-dependent signaling, *J. Biol. Chem.* 276 (2001) 39772–39778.
- [29] G.G. Tall, A.M. Kruminis, A.G. Gilman, Mammalian Ric-8A (synembryn) is a heterotrimeric Galpha protein guanine nucleotide exchange factor, *J. Biol. Chem.* 278 (2003) 8356–8362.

- [30] J.D. Hildebrandt, Role of subunit diversity in signaling by heterotrimeric G proteins, *Biochem. Pharmacol.* 54 (1997) 325–339.
- [31] G.B. Downes, N. Gautam, The G protein subunit gene families, *Genomics* 62 (1999) 544–552.
- [32] M.J. Cismowski, Non-receptor activators of heterotrimeric G-protein signaling (AGS proteins), *Semin. Cell Dev. Biol.* 17 (2006) 334–344.
- [33] J.B. Blumer, A.V. Smrcka, S.M. Lanier, Mechanistic pathways and biological roles for receptor-independent activators of G-protein signaling, *Pharmacol. Ther.* 113 (2007) 488–506.
- [34] T.E. Graham, Z. Qiao, R.I. Dorin, Dexas1 inhibits adenylyl cyclase, *Biochem. Biophys. Res. Commun.* 316 (2004) 307–312.
- [35] C.H. Nguyen, V.J. Watts, Dexas1 blocks receptor-mediated heterologous sensitization of adenylyl cyclase I, *Biochem. Biophys. Res. Commun.* 332 (2005) 913–920.
- [36] G. Vaidyanathan, M.J. Cismowski, G. Wang, T.S. Vincent, K.D. Brown, S.M. Lanier, The Ras-related protein AGS1/RASD1 suppresses cell growth, *Oncogene* 23 (2004) 5858–5863.
- [37] S.M. Lanier, A.P. Struckhoff, M.J. Cismowski, Ags1, UCSD-Nature Molecule Pages, 2007, doi:10.1038/mp.a000226.000201.
- [38] K.M. Yen, Mammalian blood loss-induced gene, kd312, US Patent #6,462,177 (1998).
- [39] H.Y. Cheng, K. Obrietan, S.W. Cain, B.Y. Lee, P.V. Agostino, N.A. Joza, M.E. Harrington, M.R. Ralph, J.M. Penninger, Dexas1 potentiates photic and suppresses nonphotic responses of the circadian clock, *Neuron* 43 (2004) 715–728.
- [40] S.M. Strittmatter, S.C. Cannon, E.M. Ross, T. Higashijima, M.C. Fishman, GAP-43 augments G protein-coupled receptor transduction in *Xenopus laevis* oocytes, *Proc. Natl. Acad. Sci. U.S.A.* 90 (1993) 5327–5331.
- [41] S. Zhou, L.S. Chen, Y. Miyauchi, M. Miyauchi, S. Kar, S. Kangavari, M.C. Fishbein, B. Sharifi, P.S. Chen, Mechanisms of cardiac nerve sprouting after myocardial infarction in dogs, *Circ. Res.* 95 (2004) 76–83.
- [42] Y. Miyauchi, S. Zhou, Y. Okuyama, M. Miyauchi, H. Hayashi, A. Hamabe, M.C. Fishbein, W.J. Mandel, L.S. Chen, P.S. Chen, et al., Altered atrial electrical restitution and heterogeneous sympathetic hyperinnervation in hearts with chronic left ventricular myocardial infarction: implications for atrial fibrillation, *Circulation* 108 (2003) 360–366.
- [43] K. Kimura, M. Ieda, H. Kanazawa, T. Yagi, M. Tsunoda, S. Ninomiya, H. Kurosawa, K. Yoshimi, H. Mochizuki, K. Yamazaki, et al., Cardiac sympathetic rejuvenation: a link between nerve function and cardiac hypertrophy, *Circ. Res.* 100 (2007) 1755–1764.
- [44] D.J. Selkoe, M.S. Wolfe, Presenilin: running with scissors in the membrane, *Cell* 131 (2007) 215–221.
- [45] M. Nakajima, E. Morizumi, H. Koseki, T. Shirasawa, Presenilin 1 is essential for cardiac morphogenesis, *Dev. Dyn.* 230 (2004) 795–799.
- [46] D. Li, S.B. Parks, J.D. Kushner, D. Nauman, D. Burgess, S. Ludwigsen, J. Partain, R.R. Nixon, C.N. Allen, R.P. Irwin, P.M. Jakobs, M. Litt, R.E. Hersberger, Mutations of presenilin genes in dilated cardiomyopathy and heart failure, *Am. J. Hum. Genet.* 79 (2006) 1030–1039.
- [47] S. Roychowdhury, M.M. Rasenick, Tubulin-G protein association stabilizes GTP binding and activates GTPase: cytoskeletal participation in neuronal signal transduction, *Biochemistry* 33 (1994) 9800–9805.
- [48] S. Roychowdhury, N. Wang, M.M. Rasenick, G protein binding and G protein activation by nucleotide transfer involve distinct domains on tubulin: regulation of signal transduction by cytoskeletal elements, *Biochemistry* 32 (1993) 4955–4961.
- [49] M.M. Rasenick, R.J. Donati, J.S. Popova, J.Z. Yu, Tubulin as a regulator of G-protein signaling, *Methods Enzymol.* 390 (2004) 389–403.
- [50] N. Wang, K. Yan, M.M. Rasenick, Tubulin binds specifically to the signal-transducing proteins, Gs alpha and Gi alpha 1, *J. Biol. Chem.* 265 (1990) 1239–1242.
- [51] M.M. Rasenick, N. Wang, Exchange of guanine nucleotides between tubulin and GTP-binding proteins that regulate adenylyl cyclase: cytoskeletal modification of neuronal signal transduction, *J. Neurochem.* 51 (1988) 300–311.
- [52] S. Roychowdhury, M.M. Rasenick, G protein beta1gamma2 subunits promote microtubule assembly, *J. Biol. Chem.* 272 (1997) 31576–31581.
- [53] M. Sato, J.B. Blumer, V. Simon, S.M. Lanier, Accessory proteins for G proteins: partners in signaling, *Annu. Rev. Pharmacol. Toxicol.* 46 (2006) 151–187.
- [54] C. Couwenbergs, A.C. Spilker, M. Gotta, Control of embryonic spindle positioning and Galpha activity by *C. elegans* RIC-8, *Curr. Biol.* 14 (2004) 1871–1876.
- [55] N. Pizzinat, A. Takesono, S.M. Lanier, Identification of a truncated form of the G-protein regulator AGS3 in heart that lacks the tetrapeptide repeat domains, *J. Biol. Chem.* 276 (2001) 16601–16610.
- [56] T. Avidor-Reiss, M. Bayewitch, R. Levy, N. Matus-Leibovitch, I. Nevo, Z. Vogel, Adenylyl cyclase supersensitization in mu-opioid receptor-transfected Chinese hamster ovary cells following chronic opioid treatment, *J. Biol. Chem.* 270 (1995) 29732–29738.
- [57] V.J. Watts, K.A. Neve, Sensitization of adenylyl cyclase by Galpha i/o-coupled receptors, *Pharmacol. Ther.* 106 (2005) 405–421.
- [58] M.S. Bowers, K. McFarland, R.W. Lake, Y.K. Peterson, C.C. Laphis, M.L. Gregory, S.M. Lanier, P.W. Kalivas, Activator of G protein signaling 3: a gatekeeper of cocaine sensitization and drug seeking, *Neuron* 42 (2004) 269–281.
- [59] L. Yao, K. McFarland, P. Fan, Z. Jiang, Y. Inoue, I. Diamond, Activator of G protein signaling 3 regulates opiate activation of protein kinase A signaling and relapse of heroin-seeking behavior, *Proc. Natl. Acad. Sci. U.S.A.* 102 (2005) 8746–8751.
- [60] J.B. Blumer, K. Lord, T.L. Saunders, A. Pacchioni, C. Black, E. Lazartigues, K.J. Varner, T.W. Gettys, S.M. Lanier, Activator of G protein signaling 3 null mice. I. Unexpected alterations in metabolic and cardiovascular function, *Endocrinology* 149 (2008) 3842–3849.
- [61] D.M. Berman, T.M. Wilkie, A.G. Gilman, GAIP and RGS4 are GTPase-activating proteins for the Gi subfamily of G protein alpha subunits, *Cell* 86 (1996) 445–452.
- [62] N. Watson, M.E. Linder, K.M. Druey, J.H. Kehrl, K.J. Blumer, RGS family members: GTPase-activating proteins for heterotrimeric G-protein alpha-subunits, *Nature* 383 (1996) 172–175.
- [63] E.L. Riddle, R.A. Schwartzman, M. Bond, P.A. Insel, Multi-tasking RGS proteins in the heart: the next therapeutic target? *Circ. Res.* 96 (2005) 401–411.
- [64] M.C. Hendriks-Balk, S.L. Peters, M.C. Michel, A.E. Alewijnse, Regulation of G protein-coupled receptor signalling: focus on the cardiovascular system and regulator of G protein signalling proteins, *Eur. J. Pharmacol.* 585 (2008) 278–291.
- [65] B. Zheng, Y.C. Ma, R.S. Ostrom, C. Lavoie, G.N. Gill, P.A. Insel, X.Y. Huang, M.G. Farquhar, RGS-PX1, a GAP for GalphaS and sorting nexin in vesicular trafficking, *Science* 294 (2001) 1939–1942.
- [66] C. Mittmann, C.H. Chung, G. Hoppner, C. Michalek, M. Nose, C. Schuler, A. Schuh, T. Eschenhagen, J. Weil, B. Pieske, et al., Expression of ten RGS proteins in human myocardium: functional characterization of an upregulation of RGS4 in heart failure, *Cardiovasc. Res.* 55 (2002) 778–786.
- [67] V.J. Owen, P.B. Burton, A.J. Mullen, E.J. Birks, P. Barton, M.H. Yacoub, Expression of RGS3, RGS4 and Gi alpha 2 in acutely failing donor hearts and end-stage heart failure, *Eur. Heart J.* 22 (2001) 1015–1020.
- [68] Y. Takeishi, T. Jalili, B.D. Hoit, D.L. Kirkpatrick, L.E. Wagoner, W.T. Abraham, R.A. Walsh, Alterations in Ca²⁺ cycling proteins and G alpha q signaling after left ventricular assist device support in failing human hearts, *Cardiovasc. Res.* 45 (2000) 883–888.
- [69] S.P. Heximer, R.H. Knutsen, X. Sun, K.M. Kaltenbronn, M.H. Rhee, N. Peng, A. Oliveira-dos-Santos, J.M. Penninger, A.J. Muslin, T.H. Steinberg, et al., Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice, *J. Clin. Invest.* 111 (2003) 445–452.
- [70] J.H. Rogers, P. Tamirisa, A. Kovacs, C. Weinheimer, M. Courtois, K.J. Blumer, D.P. Kelly, A.J. Muslin, RGS4 causes increased mortality and